Figure 3.

Acute myeloid leukemia (AML) patient-specific putative hematopoietic progenitor cells are devoid of leukemia-associated aberration. (A): Representative embryoid bodies (EBs) derived from AML patient Fib iPSCs, in hematopoietic differentiation conditions. Scale bar represents 100 µm. (B): Representative plots of flow cytometric analyses used to detect the generation and presence of CD34⁺CD45⁺ putative hematopoietic progenitors. Flow cytometric analysis for CD34⁺CD45⁺ expression was performed on a minimum of three independent hematopoietic differentiation experiments for each indicated iPSC line. Percentages represent frequency of total live cells with indicated cell surface phenotype. (C): Fluorescence in situ hybridization performed in patient-specific, EB-derived cells from one iPSC line per AML patient. Aberration identified in matched patient AML bone marrow was not detected. Adjacent plots depict the number of nuclei (blue circle) scored; 500 nuclei were analyzed to exclude 1% genetic mosaicism with 99% confidence ⁴¹. Abbreviation: iPSCs, induced pluripotent stem cells.